Kazakhstan Pharmaceuticals and Healthcare Report

 Published On: Mar, 2014 |    No of Pages: 93 |  Published By: BMI Pharmaceuticals and Healthcare | Format: PDF
Request Free Sample

View: As a new member of the Customs Union, Kazakhstan will impose a tariff on importedpharmaceuticals. This will moderately impact medium term growth in the pharmaceutical market asdemand for medicines is driven by private consumption. Nevertheless, we expect pharmaceutical spendingto accelerate as the government commits to increasing healthcare expenditure and wages continue to grow.
For multinational drug manufactures, Kazakhstan will continue to be the most attractive pharmaceuticalmarket in the Central Asian region.
Headline Expenditure Projections - Pharmaceuticals: KZT273.92bn (US$1.84bn) in 2013 to KZT302.36bn (US$2.06bn) in 2014; up 10.4%in local currency terms and 12.0% in US dollar terms.
- Healthcare: KZT1,537bn (US$10.34bn) in 2013 to KZT1,705bn (US$11.63bn) in 2014; up 10.9% inlocal currency terms and 12.5% in US dollar terms.
Risk/Reward Rating: Kazakhstan has a RRR score of 50.9 out of 100, making it the 11th most attractivepharmaceutical market in Emerging Europe. Although the Kazakh market is characterised by relatively fewmarket barriers and rapid growth, the potential rewards for the industry are moderated by low per capitaspending, an unfavourable rural-urban population split

Industry View 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Kazakhstan Pharmaceutical Sales, Historical Data and Forecasts, 2010-2018 12
Healthcare Market Forecast 13
Table: Kazakhstan Healthcare Expenditure Trends, Historical Data and Forecasts, 2010-2018 14
Table: Kazakhstan Government Healthcare Expenditure Trends, Historical Data and Forecasts 15
Table: Kazakhstan Private Healthcare Expenditure Trends, Historical Data and Forecasts 15
Prescription Drug Market Forecast 16
Table: Kazakhstan Prescription Drug Market Indicators, Historical Data and Forecasts, 2010-2018 17
Patented Drug Market Forecast 17
Table: Kazakhstan Patented Drug Market Indicators, Historical Data and Forecasts, 2010-2018 18
Generic Drug Market Forecast 19
Table: Kazakhstan Generics Drug Market Indicators, Historical Data and Forecasts 20
OTC Medicine Market Forecast 21
Table: Kazakhstan Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 22
Pharmaceutical Trade Forecast 23
Table: Kazakhstan Pharmaceutical Trade Data And Forecasts (US$mn), 2010-2018 24
Table: Kazakhstan Pharmaceutical Trade Data And Forecasts (KZTmn), 2010-2018 25
Key Risks To BMI's Forecast Scenario 26
Macroeconomic Forecasts 27
Table: Kazakhstan - Economic Activity 31
Industry Risk Reward Ratings 32
Central And Eastern Europe Risk/Reward Ratings 32
Kazakhstan Risk/Reward Ratings 38
Rewards 38
Risks 39
Market Overview 41
Industry Trends And Developments 43
Epidemiology 43
Healthcare Sector 44
Healthcare Sector Financing 46
Domestic Pharmaceutical Industry 47
Wholesale And Retail 50
Foreign Pharmaceutical Industry 52
Clinical Trials 54
Regulatory Development 55
Intellectual Property Environment 57
Pricing And Reimbursement Regime 59
Competitive Landscape 62
Company Profile 65
Chimpharm 65
Romat 67
Novartis 69
Sanofi 71
GlaxoSmithKline 73
Nycomed 75
Merck & Co77
Pfizer 78
Ranbaxy 80
Demographic Forecast 82
Table: Kazakhstan's Population By Age Group, 1990-2020 ('000) 83
Table: Kazakhstan's Population By Age Group, 1990-2020 (% of total) 84
Table: Kazakhstan's Key Population Ratios, 1990-2020 85
Table: Kazakhstan's Rural And Urban Population, 1990-2020 85
Glossary 86
Methodology 88
Pharmaceutical Expenditure Forecast Model 88
Healthcare Expenditure Forecast Model 88
Notes On Methodology 89
Risk/Reward Ratings Methodology 90
Ratings Overview 91
Table: Pharmaceutical Risk/Reward Ratings Indicators 91
Indicator Weightings 92

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.